220 related articles for article (PubMed ID: 27291066)
1. Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.
Lentz SR; Cerqueira M; Janic D; Kempton C; Matytsina I; Misgav M; Oldenburg J; Ozelo M; Recht M; Rosholm A; Savic A; Suzuki T; Tiede A; Santagostino E
Haemophilia; 2016 Sep; 22(5):e445-9. PubMed ID: 27291066
[No Abstract] [Full Text] [Related]
2. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial.
Ozelo M; Misgav M; Abdul Karim F; Lentz SR; Martin-Salces M; Matytsina I; Saugstrup T; Santagostino E
Haemophilia; 2015 Sep; 21(5):e436-9. PubMed ID: 26058730
[No Abstract] [Full Text] [Related]
3. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
[TBL] [Abstract][Full Text] [Related]
4. Updates from guardian™: a comprehensive registration programme.
Ozelo MC
Eur J Haematol; 2015 Dec; 95 Suppl 81():22-9. PubMed ID: 26679394
[TBL] [Abstract][Full Text] [Related]
5. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
[TBL] [Abstract][Full Text] [Related]
6. Impact of severe haemophilia A on patients' health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) ).
Ozelo M; Chowdary P; Regnault A; Busk AK
Haemophilia; 2015 Jul; 21(4):451-7. PubMed ID: 25677761
[TBL] [Abstract][Full Text] [Related]
7. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.
Santagostino E; Lentz SR; Misgav M; Brand B; Chowdary P; Savic A; Kilinc Y; Amit Y; Amendola A; Solimeno LP; Saugstrup T; Matytsina I
Haemophilia; 2015 Jan; 21(1):34-40. PubMed ID: 25273984
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
[TBL] [Abstract][Full Text] [Related]
10. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
[TBL] [Abstract][Full Text] [Related]
11. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.
Khair K; Mazzucconi MG; Parra R; Santagostino E; Tsakiris DA; Hermans C; Oldenburg J; Spotts G; Steinitz-Trost K; Gringeri A
Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825
[TBL] [Abstract][Full Text] [Related]
12. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.
Crivianu-Gaita V; Rivard GE; Carcao M; Teitel J; St-Louis J; Blanchette V; Pullenayegum E; Abad A; Feldman BM
Haemophilia; 2016 Sep; 22(5):e401-5. PubMed ID: 27481574
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.
Boban A; Hermans C
Expert Rev Hematol; 2020 Apr; 13(4):303-311. PubMed ID: 32153219
[No Abstract] [Full Text] [Related]
15. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
[TBL] [Abstract][Full Text] [Related]
16. Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.
Tiede A; Klamroth R; Oldenburg J
Hamostaseologie; 2015; 35(4):364-71. PubMed ID: 26271775
[TBL] [Abstract][Full Text] [Related]
17. Tranexamic acid in the control of spontaneous bleeding in severe haemophilia.
Rainsford SG; Jouhar AJ; Hall A
Thromb Diath Haemorrh; 1973 Nov; 30(2):272-9. PubMed ID: 4773366
[No Abstract] [Full Text] [Related]
18. Successful perioperative prophylaxis with susoctocog alfa in a patient with acquired haemophilia A: A case study.
Buczma A; Baran B; Korwin M; Odnoczko E; Windyga J
Haemophilia; 2022 Mar; 28(2):e39-e41. PubMed ID: 34878208
[No Abstract] [Full Text] [Related]
19. Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
Mathias M; Abashidze M; Abraham A; Belletrutti MJ; Carcao M; Chambost H; Chan AKC; Dubey L; Ducore J; Lambert T; Kavardakova N; Lohade S; Turea V; Wu JKM; Klukowska A
Haemophilia; 2023 Jul; 29(4):1005-1012. PubMed ID: 37335546
[TBL] [Abstract][Full Text] [Related]
20. Experience with prophylaxis in Sweden.
Nilsson IM
Semin Hematol; 1993 Jul; 30(3 Suppl 2):16-9. PubMed ID: 8367738
[No Abstract] [Full Text] [Related]
[Next] [New Search]